138 related articles for article (PubMed ID: 19378689)
1. Incidence, patient characteristics and predictors of aborted myocardial infarction in patients undergoing primary PCI: prospective study comparing pre- and in-hospital abciximab pretreatment.
Hassan AK; Jukema JW; van der Laarse A; Hasan-Ali H; Wolterbeek R; van der Kley F; Spano F; Atsma DE; Schalij MJ
EuroIntervention; 2009 Mar; 4(5):662-8. PubMed ID: 19378689
[TBL] [Abstract][Full Text] [Related]
2. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
3. Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.
Eitel I; Desch S; Schindler K; Fuernau G; Schuler G; Thiele H
Int J Cardiol; 2011 Nov; 153(1):21-5. PubMed ID: 20817283
[TBL] [Abstract][Full Text] [Related]
4. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
[TBL] [Abstract][Full Text] [Related]
5. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study.
Rakowski T; Zalewski J; Legutko J; Bartus S; Rzeszutko L; Dziewierz A; Sorysz D; Bryniarski L; Zmudka K; Kaluza GL; Dubiel JS; Dudek D
Am Heart J; 2007 Mar; 153(3):360-5. PubMed ID: 17307412
[TBL] [Abstract][Full Text] [Related]
6. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
[TBL] [Abstract][Full Text] [Related]
7. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial.
Marzocchi A; Manari A; Piovaccari G; Marrozzini C; Marra S; Magnavacchi P; Sangiorgio P; Marinucci L; Taglieri N; Gordini G; Binetti N; Guiducci V; Franco N; Reggiani ML; Saia F;
Eur Heart J; 2008 Dec; 29(24):2972-80. PubMed ID: 18940887
[TBL] [Abstract][Full Text] [Related]
9. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry).
Dziewierz A; Mielecki W; Siudak Z; Rakowski T; Janzon M; Birkemeyer R; Zasada W; Dubiel JS; Dudek D
Atherosclerosis; 2012 Jul; 223(1):212-8. PubMed ID: 22658254
[TBL] [Abstract][Full Text] [Related]
10. Intracoronary compared to intravenous abciximab in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year.
Iversen AZ; Galatius S; Abildgaard U; Galloe A; Hansen PR; Pedersen S; Engstroem T; Jensen JS
Cardiology; 2011; 120(1):43-9. PubMed ID: 22122887
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
12. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Garg S; Sarno G; Serruys PW; Rodriguez AE; Bolognese L; Anselmi M; De Cesare N; Colangelo S; Moreno R; Gambetti S; Monti M; Bristot L; Bressers M; Garcia-Garcia HM; Parrinello G; Campo G; Valgimigli M;
JACC Cardiovasc Interv; 2011 Jan; 4(1):66-75. PubMed ID: 21251631
[TBL] [Abstract][Full Text] [Related]
13. Aspiration thrombectomy during primary percutaneous coronary intervention as adjunctive therapy to early (in-ambulance) abciximab administration in patients with acute ST elevation myocardial infarction: an analysis from Leiden MISSION! acute myocardial infarction treatment optimization program.
Ahmed TA; Atary JZ; Wolterbeek R; Hasan-Ali H; Abdel-Kader SS; Schalij MJ; Jukema JW
J Interv Cardiol; 2012 Feb; 25(1):1-9. PubMed ID: 22059390
[TBL] [Abstract][Full Text] [Related]
14. Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention.
Dudek D; Rakowski T; Bartus S; Giszterowicz D; Dobrowolski W; Zmudka K; Zalewski J; Ochala A; Wieja P; Janus B; Dziewierz A; Legutko J; Bryniarski L; Dubiel JS
J Thromb Thrombolysis; 2010 Oct; 30(3):347-53. PubMed ID: 20373130
[TBL] [Abstract][Full Text] [Related]
15. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW
J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418
[TBL] [Abstract][Full Text] [Related]
16. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry.
Dudek D; Siudak Z; Janzon M; Birkemeyer R; Aldama-Lopez G; Lettieri C; Janus B; Wisniewski A; Berti S; Olivari Z; Rakowski T; Partyka L; Goedicke J; Zmudka K;
Am Heart J; 2008 Dec; 156(6):1147-54. PubMed ID: 19033011
[TBL] [Abstract][Full Text] [Related]
17. Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H; Wöhrle J; Neuhaus P; Brosteanu O; Sick P; Prondzinsky R; Birkemeyer R; Wiemer M; Kerber S; Schuehlen H; Kleinertz K; Axthelm C; Zimmermann R; Rittger H; Braun-Dullaeus RC; Lauer B; Burckhardt W; Ferrari M; Bergmann MW; Hambrecht R; Schuler G;
Am Heart J; 2010 Apr; 159(4):547-54. PubMed ID: 20362711
[TBL] [Abstract][Full Text] [Related]
18. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
[TBL] [Abstract][Full Text] [Related]
19. Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry.
Siudak Z; Rakowski T; Dziewierz A; Janzon M; Birkemeyer R; Stefaniak J; Partyka Ł; Zmudka K; Dudek D
Kardiol Pol; 2010 May; 68(5):539-43. PubMed ID: 20491016
[TBL] [Abstract][Full Text] [Related]
20. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
